Why the study?
What are the pharmacokinetic properties of extended-release isosorbide 5-mononitrate in patients with acute myocardial infarction?
Population
18 patients with acute myocardial infarction (AMI)
Design
Cohort
Follow-up
5 to 7 days
Authors
Loading...
Informs dosing in AMI; extends steady-state PK data from healthy volunteers to this population.
What are the pharmacokinetic properties of extended-release isosorbide 5-mononitrate in patients with acute myocardial infarction?
Extended-release isosorbide 5-mononitrate shows similar steady-state kinetics in AMI patients as in healthy volunteers, though initial absorption may be delayed by concomitant morphine.
McClennen et al. (1995) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: